Currently out of the existing stock ratings of Richard Law, 27 are a HOLD (60%), 17 are a BUY (37.78%), 1 are a SELL (2.22%).

Richard Law

Work Performance Price Targets & Ratings Chart

Analyst Richard Law works at CREDIT SUISSE with a stock forecast success ratio of 31.49% fulfilled within 70.55 days on average.

Richard Law’s has documented 91 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VERV, Verve Therapeutics at 11-Aug-2023.

Wall Street Analyst Richard Law

Analyst best performing recommendations are on OLMA (OLEMA PHARMACEUTICALS).
The best stock recommendation documented was for FIXX (HOMOLOGY MEDICINES) at 5/17/2022. The price target of $2.1 was fulfilled within 21 days with a profit of $0.59 (39.07%) receiving and performance score of 18.61.

Average potential price target upside

ARVN Arvinas BEAM Beam Therapeutics  CRSP Crispr Therapeutics AG FIXX Homology Medicines KYMR Kymera Therapeutics NTLA Intellia Therapeutics EDIT Editas Medicine CCCC C4 Therapeutics  GLUE Monte Rosa Therapeutics OLMA Olema Pharmaceuticals VERV Verve Therapeutics

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

55

$8.49 (18.25%)

36

8 days ago

5/12 (41.67%)

$7.23 (15.14%)

175

Buy

70

$23.49 (50.51%)

22 days ago

0/3 (0%)

$24.35 (53.34%)

Buy

63

$16.49 (35.45%)

49

2 months 4 days ago

1/3 (33.33%)

$25.13 (66.36%)

403

Buy

40

$-6.51 (-14.00%)

42

2 months 17 days ago

2/2 (100%)

$9.7 (32.01%)

11

Hold

20

$-26.51 (-57.00%)

32

3 months 10 days ago

12/13 (92.31%)

$3.41 (20.55%)

84

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Richard Law?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?